• LAST PRICE
    0.0214
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 0.0214
  • Day Range
    ---
  • 52 Week Range
    Low 0.0150
    High 0.0898
  • Volume
    ---

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table
TimeVolumeGTHR
Data delayed at least 15 minutes.
No documents available
0 New Today
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGTHR
GeneThera Inc
756.1K
-0.8x
---
United StatesRSPI
RespireRx Pharmaceuticals Inc
705.6K
-0.3x
---
United StatesHSTC
HST Global Inc
682.8K
-4.7x
---
United StatesVGLS
VG Life Sciences Inc
901.9K
0.0x
---
United StatesHDVY
Health Discovery Corp
988.1K
-0.3x
---
United StatesRBSH
Rebus Holdings Inc
482.0K
0.2x
---
As of 2022-09-28

Company Information

GeneThera, Inc. is a biotechnology company. The Company is focused on developing genetics-based diagnostic assays and vaccine solutions and molecular diagnostic tests, therapeutics, and vaccines through its technologies for controlling the spread of zoonotic infection. The Company has developed a Molecular Robotic/AI Laboratory Platform (MORAP), which combine the use of advanced robotic laboratory systems integrated with artificial intelligence software systems. Its MORAPAT is designed to prevent the spread of disease from animals and control zoonotic infectious agents. The Company has also developed a large-scale process for highly purified and high viral titer (viral concentration) Adenovirus and Adeno-associated virus (AAV) genetically engineered viruses. This technology develops Adenovirus and AAV-based recombinant DNA vaccines for zoonotic pathogens. PURIVAX is a purification system that enhances biological purity and viral titer of recombinant Adenovirus and AAV vectors.

Contact Information

Headquarters
3051 W 105Th Avenue, Unit 350251WESTMINSTER, CO, United States 80031
Phone
720-587-5100
Fax
702-866-2689

Executives

Chairman of the Board, Chief Executive Officer, Chief Scientific Officer
Antonio Milici
Interim Chief Financial Officer, Chief Administrative Officer
Tannya Irizarry
Director
Jeremiah Bartley

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$756.1K
Revenue (TTM)
$0.00
Shares Outstanding
35.3M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
0.37
EPS
$-0.03
Book Value
$-0.24
P/E Ratio
-0.8x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.